The total return over the past 12 months is -41.12% vs. +16.94% for the S&P 500. So far it's up -24.93% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (41.12%) | (6.86%) | (23.91%) | (23.59%) | N/A | N/A |
| Total Return CAGR | (41.12%) | (6.86%) | (23.91%) | (23.59%) | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Larimar Therapeutics, Inc. (LRMR)
| Year | Start price | End price | LRMR Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $3.81 | $2.86 | (24.93%) | +14.51% | (39.44%) |
| 2025 | $3.87 | $3.81 | (1.55%) | +17.72% | (19.27%) |
| 2024 | $4.55 | $3.87 | (14.95%) | +24.89% | (39.84%) |
| 2023 | $4.13 | $4.55 | +10.17% | +26.19% | (16.02%) |
| 2022 | $10.79 | $4.13 | (61.72%) | (18.17%) | (43.55%) |
| 2021 | $21.41 | $10.79 | (49.60%) | +28.74% | (78.34%) |
| 2020 | $13.32 | $21.41 | +60.74% | +18.37% | +42.37% |
| 2019 | $59.40 | $13.32 | (77.58%) | +31.22% | (108.80%) |
| 2018 | $55.44 | $59.40 | +7.14% | (4.56%) | +11.70% |
| 2017 | $38.16 | $55.44 | +45.28% | +21.70% | +23.58% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
